Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Memorial Sloan Kettering Cancer Center · Texas Oncology · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
940
total citations
- FWCI
- 68.53
- Percentile
- 100%
- References
- 23
Citations per year
Authors
17- RJRobert J. MotzerCorresponding
Memorial Sloan Kettering Cancer Center
- TEThomas E. Hutson
Texas Oncology
- HGHilary Glen
Beatson West of Scotland Cancer Centre
- MDM. Dror Michaelson
Massachusetts General Hospital
- AMAna M. Molina
NewYork–Presbyterian Hospital, Cornell University, New York Hospital Queens, Presbyterian Hospital
Topics & keywords
Topics
Keywords
- Everolimus
- Lenvatinib
- Medicine
- Renal cell carcinoma
- Internal medicine
- Oncology
- Population
- Sorafenib
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.